BACKGROUND: Data on the influence of gonadal hormones on incident fracture risk in elderly men are limited. We prospectively examined the relationship between serum levels of testosterone and estradiol and future fracture risk in community-dwelling men. METHODS: A total of 609 men older than 60 years had been observed between January 1989 and December 2005, with the median duration being 5.8 years (up to 13 years). Clinical risk factors, including bone mineral density and lifestyle factors, were assessed at baseline. Serum testosterone and estradiol levels were measured by tandem mass spectrometry. The incidence of a low-trauma fracture was ascertained during follow-up. RESULTS: During follow-up, 113 men had at least 1 low-trauma fracture. The risk of fracture was significantly increased in men with reduced testosterone levels (hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.09-1.62). After adjustment for sex hormone-binding globulin, serum testosterone (HR, 1.48; 95% CI, 1.22-1.78) and serum estradiol (HR, 1.21; 95% CI, 1.00-1.47) levels were associated with overall fracture risk. After further adjustment for major risk factors of fractures (age, weight or bone mineral density, fracture history, smoking status, calcium intake, and sex hormone-binding globulin), lower testosterone was still associated with increased risk of fracture, particularly with hip (HR, 1.88; 95% CI, 1.24-2.82) and nonvertebral (HR, 1.32; 95% CI, 1.03-1.68) fractures. CONCLUSION: In community-dwelling men older than 60 years, serum testosterone is independently associated with the risk of osteoporotic fracture and its measurement may provide additional clinical information for the assessment of fracture risk in elderly men.
BACKGROUND: Data on the influence of gonadal hormones on incident fracture risk in elderly men are limited. We prospectively examined the relationship between serum levels of testosterone and estradiol and future fracture risk in community-dwelling men. METHODS: A total of 609 men older than 60 years had been observed between January 1989 and December 2005, with the median duration being 5.8 years (up to 13 years). Clinical risk factors, including bone mineral density and lifestyle factors, were assessed at baseline. Serum testosterone and estradiol levels were measured by tandem mass spectrometry. The incidence of a low-trauma fracture was ascertained during follow-up. RESULTS: During follow-up, 113 men had at least 1 low-trauma fracture. The risk of fracture was significantly increased in men with reduced testosterone levels (hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.09-1.62). After adjustment for sex hormone-binding globulin, serum testosterone (HR, 1.48; 95% CI, 1.22-1.78) and serum estradiol (HR, 1.21; 95% CI, 1.00-1.47) levels were associated with overall fracture risk. After further adjustment for major risk factors of fractures (age, weight or bone mineral density, fracture history, smoking status, calcium intake, and sex hormone-binding globulin), lower testosterone was still associated with increased risk of fracture, particularly with hip (HR, 1.88; 95% CI, 1.24-2.82) and nonvertebral (HR, 1.32; 95% CI, 1.03-1.68) fractures. CONCLUSION: In community-dwelling men older than 60 years, serum testosterone is independently associated with the risk of osteoporotic fracture and its measurement may provide additional clinical information for the assessment of fracture risk in elderly men.
Authors: Elizabeth Barrett-Connor; Gail A Laughlin; Hong Li; Carrie M Nielson; P Ying Wang; Tien T Dam; Jane A Cauley; Kristine E Ensrud; Marcia L Stefanick; Edith Lau; Andrew R Hoffman; Eric S Orwoll Journal: J Bone Miner Res Date: 2012-11 Impact factor: 6.741
Authors: S Scholtissen; F Guillemin; O Bruyère; J Collette; B Dousset; C Kemmer; S Culot; D Crémer; H Dejardin; G Hubermont; D Lefebvre; V Pascal-Vigneron; G Weryha; J Y Reginster Journal: Osteoporos Int Date: 2008-11-15 Impact factor: 4.507
Authors: J P Steffens; B S Herrera; L S Coimbra; D N Stephens; C Rossa; L C Spolidorio; A Kantarci; T E Van Dyke Journal: Horm Metab Res Date: 2014-02-13 Impact factor: 2.936
Authors: D Vanderschueren; S R Pye; K Venken; H Borghs; J Gaytant; I T Huhtaniemi; J E Adams; K A Ward; G Bartfai; F F Casanueva; J D Finn; G Forti; A Giwercman; T S Han; K Kula; F Labrie; M E J Lean; N Pendleton; M Punab; A J Silman; F C W Wu; T W O'Neill; S Boonen Journal: Osteoporos Int Date: 2009-12-15 Impact factor: 4.507
Authors: L Jørgensen; T Skjelbakken; M-L Løchen; L Ahmed; A Bjørnerem; R Joakimsen; B K Jacobsen Journal: Osteoporos Int Date: 2009-12-03 Impact factor: 4.507